{"id":61847,"date":"2025-09-11T04:06:51","date_gmt":"2025-09-11T02:06:51","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/contrast-enhanced-ultrasound-shows-100-sensitivity-and-specificity-for-finding-residual-or-recurrent-kidney-tumors\/"},"modified":"2025-09-11T04:06:51","modified_gmt":"2025-09-11T02:06:51","slug":"contrast-enhanced-ultrasound-shows-100-sensitivity-and-specificity-for-finding-residual-or-recurrent-kidney-tumors","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/contrast-enhanced-ultrasound-shows-100-sensitivity-and-specificity-for-finding-residual-or-recurrent-kidney-tumors\/","title":{"rendered":"Contrast Enhanced Ultrasound Shows 100% Sensitivity and Specificity for Finding Residual or Recurrent Kidney Tumors"},"content":{"rendered":"
\n

CHICAGO–(BUSINESS WIRE)–#CEUS<\/a>–Contrast enhanced ultrasound (CEUS) is superior to contrast magnetic resonance (MR) and computed tomography (CT), and offers 100% sensitivity and specificity, for finding residual or recurrent kidney tumors in patients who have had a kidney-sparing procedure, according to a new study announced today at the 39th<\/sup> annual International Bubble Conference in Chicago.<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe study assessed 193 kidney lesions in 188 patients at two medical centers over approximately six years, according to the principal investigator, Dr. Richard G. Barr, Professor of Radiology at Northeast Ohio Medical University and an officer of the International Contrast Ultrasound Society, who spoke at the conference.<\/p>\n

\n\u201cNephron sparing procedures are now widely used to treat renal cell carcinomas, and follow up is important because recurrence can occur several years later,\u201d Dr. Barr said.<\/p>\n

\nCEUS uses ultrasound contrast agents (UCAs), which are administered intravenously to enhance the images produced by ultrasound scans, allowing for visualization of abnormal microvascular blood flow patterns in real time.<\/p>\n

\nCEUS is safely and routinely used worldwide to help identify and characterize cancers, diagnose heart and vascular disease, monitor chronic gastro-intestinal diseases and monitor therapy.<\/p>\n

\n\u201cCEUS is a less expensive examination when compared to contrast MR or CT, and it does a better job of detecting residual or recurring cancer cells in the treated renal cancer while also avoiding the radiation of CT and possible kidney impairment of CT and MR contrast agents,\u201d he added.<\/p>\n

\nIn addition, contrast CT or MR are not options for many patients with impaired kidneys due to potential nephrotoxicity or allergic reactions to the CT or MR contrast agents. Ultrasound contrast agents do not contain iodine or gadolinium, and are not nephrotoxic.<\/p>\n

\nRenal cell carcinoma is the 13th<\/sup> most common cause of cancer death worldwide.<\/p>\n

\nFour ultrasound contrast agents are available in various countries around the world: Sonovue (Lumason in the USA), manufactured and sold by Bracco; Definity, manufactured and sold by Lantheus; and Optison and Sonazoid, manufactured and sold by GE Healthcare.<\/p>\n

\nABOUT ICUS:<\/b><\/p>\n

\nThe International Contrast Ultrasound Society (ICUS) is a nonprofit medical society dedicated to advancing the safe and medically appropriate use of contrast enhanced ultrasound (CEUS) to improve patient care globally. Membership in ICUS is free of charge and there is no fee for ICUS educational programs, CME credits, newsletters or other resources.<\/p>\n

\nTo join ICUS and learn more about CEUS, visit www.icus-society.org<\/a> and download ICUS CONNECT, the free ICUS mobile app.<\/p>\n

Contacts<\/b> <\/p>\n

\nInternational Contrast Ultrasound Society<\/b>
Linda Maiman Feinstein, Advisor — 847-624-1844 or 312-876-2563, Linda.Feinstein@Dentons.com<\/a>
Robin J. Adams, Director of Communication — 202-408-3946, Robin.Adams@Dentons.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

CHICAGO–(BUSINESS WIRE)–#CEUS–Contrast enhanced ultrasound (CEUS) is superior to contrast magnetic resonance (MR) and computed tomography (CT), and offers 100% sensitivity and specificity, for finding residual or recurrent kidney tumors in patients who have had a kidney-sparing procedure, according to a new study announced today at the 39th annual International Bubble Conference in Chicago. The study … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61847","6":"format-standard","7":"category-industry"},"yoast_head":"\nContrast Enhanced Ultrasound Shows 100% Sensitivity and Specificity for Finding Residual or Recurrent Kidney Tumors - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/contrast-enhanced-ultrasound-shows-100-sensitivity-and-specificity-for-finding-residual-or-recurrent-kidney-tumors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Contrast Enhanced Ultrasound Shows 100% Sensitivity and Specificity for Finding Residual or Recurrent Kidney Tumors - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"CHICAGO–(BUSINESS WIRE)–#CEUS–Contrast enhanced ultrasound (CEUS) is superior to contrast magnetic resonance (MR) and computed tomography (CT), and offers 100% sensitivity and specificity, for finding residual or recurrent kidney tumors in patients who have had a kidney-sparing procedure, according to a new study announced today at the 39th annual International Bubble Conference in Chicago. The study ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/contrast-enhanced-ultrasound-shows-100-sensitivity-and-specificity-for-finding-residual-or-recurrent-kidney-tumors\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-11T02:06:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250910313186\/en\/2577109\/22\/ICUS_Logo_blue_bg.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/contrast-enhanced-ultrasound-shows-100-sensitivity-and-specificity-for-finding-residual-or-recurrent-kidney-tumors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/contrast-enhanced-ultrasound-shows-100-sensitivity-and-specificity-for-finding-residual-or-recurrent-kidney-tumors\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Contrast Enhanced Ultrasound Shows 100% Sensitivity and Specificity for Finding Residual or Recurrent Kidney Tumors\",\"datePublished\":\"2025-09-11T02:06:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/contrast-enhanced-ultrasound-shows-100-sensitivity-and-specificity-for-finding-residual-or-recurrent-kidney-tumors\\\/\"},\"wordCount\":447,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/contrast-enhanced-ultrasound-shows-100-sensitivity-and-specificity-for-finding-residual-or-recurrent-kidney-tumors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250910313186\\\/en\\\/2577109\\\/22\\\/ICUS_Logo_blue_bg.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/contrast-enhanced-ultrasound-shows-100-sensitivity-and-specificity-for-finding-residual-or-recurrent-kidney-tumors\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/contrast-enhanced-ultrasound-shows-100-sensitivity-and-specificity-for-finding-residual-or-recurrent-kidney-tumors\\\/\",\"name\":\"Contrast Enhanced Ultrasound Shows 100% Sensitivity and Specificity for Finding Residual or Recurrent Kidney Tumors - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/contrast-enhanced-ultrasound-shows-100-sensitivity-and-specificity-for-finding-residual-or-recurrent-kidney-tumors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/contrast-enhanced-ultrasound-shows-100-sensitivity-and-specificity-for-finding-residual-or-recurrent-kidney-tumors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250910313186\\\/en\\\/2577109\\\/22\\\/ICUS_Logo_blue_bg.jpg\",\"datePublished\":\"2025-09-11T02:06:51+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/contrast-enhanced-ultrasound-shows-100-sensitivity-and-specificity-for-finding-residual-or-recurrent-kidney-tumors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/contrast-enhanced-ultrasound-shows-100-sensitivity-and-specificity-for-finding-residual-or-recurrent-kidney-tumors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/contrast-enhanced-ultrasound-shows-100-sensitivity-and-specificity-for-finding-residual-or-recurrent-kidney-tumors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250910313186\\\/en\\\/2577109\\\/22\\\/ICUS_Logo_blue_bg.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250910313186\\\/en\\\/2577109\\\/22\\\/ICUS_Logo_blue_bg.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/contrast-enhanced-ultrasound-shows-100-sensitivity-and-specificity-for-finding-residual-or-recurrent-kidney-tumors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Contrast Enhanced Ultrasound Shows 100% Sensitivity and Specificity for Finding Residual or Recurrent Kidney Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Contrast Enhanced Ultrasound Shows 100% Sensitivity and Specificity for Finding Residual or Recurrent Kidney Tumors - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/contrast-enhanced-ultrasound-shows-100-sensitivity-and-specificity-for-finding-residual-or-recurrent-kidney-tumors\/","og_locale":"en_US","og_type":"article","og_title":"Contrast Enhanced Ultrasound Shows 100% Sensitivity and Specificity for Finding Residual or Recurrent Kidney Tumors - Pharma Trend","og_description":"CHICAGO–(BUSINESS WIRE)–#CEUS–Contrast enhanced ultrasound (CEUS) is superior to contrast magnetic resonance (MR) and computed tomography (CT), and offers 100% sensitivity and specificity, for finding residual or recurrent kidney tumors in patients who have had a kidney-sparing procedure, according to a new study announced today at the 39th annual International Bubble Conference in Chicago. The study ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/contrast-enhanced-ultrasound-shows-100-sensitivity-and-specificity-for-finding-residual-or-recurrent-kidney-tumors\/","og_site_name":"Pharma Trend","article_published_time":"2025-09-11T02:06:51+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250910313186\/en\/2577109\/22\/ICUS_Logo_blue_bg.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/contrast-enhanced-ultrasound-shows-100-sensitivity-and-specificity-for-finding-residual-or-recurrent-kidney-tumors\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/contrast-enhanced-ultrasound-shows-100-sensitivity-and-specificity-for-finding-residual-or-recurrent-kidney-tumors\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Contrast Enhanced Ultrasound Shows 100% Sensitivity and Specificity for Finding Residual or Recurrent Kidney Tumors","datePublished":"2025-09-11T02:06:51+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/contrast-enhanced-ultrasound-shows-100-sensitivity-and-specificity-for-finding-residual-or-recurrent-kidney-tumors\/"},"wordCount":447,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/contrast-enhanced-ultrasound-shows-100-sensitivity-and-specificity-for-finding-residual-or-recurrent-kidney-tumors\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250910313186\/en\/2577109\/22\/ICUS_Logo_blue_bg.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/contrast-enhanced-ultrasound-shows-100-sensitivity-and-specificity-for-finding-residual-or-recurrent-kidney-tumors\/","url":"https:\/\/pharma-trend.com\/en\/contrast-enhanced-ultrasound-shows-100-sensitivity-and-specificity-for-finding-residual-or-recurrent-kidney-tumors\/","name":"Contrast Enhanced Ultrasound Shows 100% Sensitivity and Specificity for Finding Residual or Recurrent Kidney Tumors - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/contrast-enhanced-ultrasound-shows-100-sensitivity-and-specificity-for-finding-residual-or-recurrent-kidney-tumors\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/contrast-enhanced-ultrasound-shows-100-sensitivity-and-specificity-for-finding-residual-or-recurrent-kidney-tumors\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250910313186\/en\/2577109\/22\/ICUS_Logo_blue_bg.jpg","datePublished":"2025-09-11T02:06:51+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/contrast-enhanced-ultrasound-shows-100-sensitivity-and-specificity-for-finding-residual-or-recurrent-kidney-tumors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/contrast-enhanced-ultrasound-shows-100-sensitivity-and-specificity-for-finding-residual-or-recurrent-kidney-tumors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/contrast-enhanced-ultrasound-shows-100-sensitivity-and-specificity-for-finding-residual-or-recurrent-kidney-tumors\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250910313186\/en\/2577109\/22\/ICUS_Logo_blue_bg.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250910313186\/en\/2577109\/22\/ICUS_Logo_blue_bg.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/contrast-enhanced-ultrasound-shows-100-sensitivity-and-specificity-for-finding-residual-or-recurrent-kidney-tumors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Contrast Enhanced Ultrasound Shows 100% Sensitivity and Specificity for Finding Residual or Recurrent Kidney Tumors"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61847","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61847"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61847\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61847"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61847"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61847"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}